Cargando…

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmani, Nora E., Ramachandra, Nandini, Sahu, Srabani, Gitego, Nadege, Lopez, Andrea, Pradhan, Kith, Bhagat, Tushar D., Gordon-Mitchell, Shanisha, Pena, Bianca Rivera, Kazemi, Mohammad, Rao, Keshav, Giricz, Orsi, Maqbool, Shahina Bano, Olea, Raul, Zhao, Yongmei, Zhang, Jinghang, Dolatshad, Hamid, Tittrea, Vickram, Tatwavedi, Dharamveer, Singh, Shalini, Lee, Juseong, Sun, Tianyu, Steidl, Ulrich, Shastri, Aditi, Inoue, Daichi, Abdel-Wahab, Omar, Pellagatti, Andrea, Gavathiotis, Evripidis, Boultwood, Jacqueline, Verma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455571/
https://www.ncbi.nlm.nih.gov/pubmed/34548471
http://dx.doi.org/10.1038/s41408-021-00541-0
_version_ 1784570695607386112
author Rahmani, Nora E.
Ramachandra, Nandini
Sahu, Srabani
Gitego, Nadege
Lopez, Andrea
Pradhan, Kith
Bhagat, Tushar D.
Gordon-Mitchell, Shanisha
Pena, Bianca Rivera
Kazemi, Mohammad
Rao, Keshav
Giricz, Orsi
Maqbool, Shahina Bano
Olea, Raul
Zhao, Yongmei
Zhang, Jinghang
Dolatshad, Hamid
Tittrea, Vickram
Tatwavedi, Dharamveer
Singh, Shalini
Lee, Juseong
Sun, Tianyu
Steidl, Ulrich
Shastri, Aditi
Inoue, Daichi
Abdel-Wahab, Omar
Pellagatti, Andrea
Gavathiotis, Evripidis
Boultwood, Jacqueline
Verma, Amit
author_facet Rahmani, Nora E.
Ramachandra, Nandini
Sahu, Srabani
Gitego, Nadege
Lopez, Andrea
Pradhan, Kith
Bhagat, Tushar D.
Gordon-Mitchell, Shanisha
Pena, Bianca Rivera
Kazemi, Mohammad
Rao, Keshav
Giricz, Orsi
Maqbool, Shahina Bano
Olea, Raul
Zhao, Yongmei
Zhang, Jinghang
Dolatshad, Hamid
Tittrea, Vickram
Tatwavedi, Dharamveer
Singh, Shalini
Lee, Juseong
Sun, Tianyu
Steidl, Ulrich
Shastri, Aditi
Inoue, Daichi
Abdel-Wahab, Omar
Pellagatti, Andrea
Gavathiotis, Evripidis
Boultwood, Jacqueline
Verma, Amit
author_sort Rahmani, Nora E.
collection PubMed
description The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1(G710X) mutation showed reduced leukemic growth, increased myeloid differentiation, and decreased HOXA and BCL2 gene expression in vitro compared to uncorrected KBM5 cells. Increased expression of the anti-apoptotic gene, BCL2, was also observed in bone marrow CD34+ cells from ASXL1 mutant MDS patients compared to CD34+ cells from wild-type MDS cases. ATAC-sequencing demonstrated open chromatin at the BCL2 promoter in the ASXL1 mutant KBM5 cells. BH3 profiling demonstrated increased dependence of mutant cells on BCL2. Upon treatment with VEN, mutant cells demonstrated increased growth inhibition. In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA. These data mechanistically link the common leukemia-associated mutation ASXL1 to enhanced sensitivity to VEN and AZA via epigenetic upregulation of BCL2 expression and widespread alterations in DNA methylation.
format Online
Article
Text
id pubmed-8455571
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84555712021-10-07 ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine Rahmani, Nora E. Ramachandra, Nandini Sahu, Srabani Gitego, Nadege Lopez, Andrea Pradhan, Kith Bhagat, Tushar D. Gordon-Mitchell, Shanisha Pena, Bianca Rivera Kazemi, Mohammad Rao, Keshav Giricz, Orsi Maqbool, Shahina Bano Olea, Raul Zhao, Yongmei Zhang, Jinghang Dolatshad, Hamid Tittrea, Vickram Tatwavedi, Dharamveer Singh, Shalini Lee, Juseong Sun, Tianyu Steidl, Ulrich Shastri, Aditi Inoue, Daichi Abdel-Wahab, Omar Pellagatti, Andrea Gavathiotis, Evripidis Boultwood, Jacqueline Verma, Amit Blood Cancer J Article The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1(G710X) mutation showed reduced leukemic growth, increased myeloid differentiation, and decreased HOXA and BCL2 gene expression in vitro compared to uncorrected KBM5 cells. Increased expression of the anti-apoptotic gene, BCL2, was also observed in bone marrow CD34+ cells from ASXL1 mutant MDS patients compared to CD34+ cells from wild-type MDS cases. ATAC-sequencing demonstrated open chromatin at the BCL2 promoter in the ASXL1 mutant KBM5 cells. BH3 profiling demonstrated increased dependence of mutant cells on BCL2. Upon treatment with VEN, mutant cells demonstrated increased growth inhibition. In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA. These data mechanistically link the common leukemia-associated mutation ASXL1 to enhanced sensitivity to VEN and AZA via epigenetic upregulation of BCL2 expression and widespread alterations in DNA methylation. Nature Publishing Group UK 2021-09-21 /pmc/articles/PMC8455571/ /pubmed/34548471 http://dx.doi.org/10.1038/s41408-021-00541-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Rahmani, Nora E.
Ramachandra, Nandini
Sahu, Srabani
Gitego, Nadege
Lopez, Andrea
Pradhan, Kith
Bhagat, Tushar D.
Gordon-Mitchell, Shanisha
Pena, Bianca Rivera
Kazemi, Mohammad
Rao, Keshav
Giricz, Orsi
Maqbool, Shahina Bano
Olea, Raul
Zhao, Yongmei
Zhang, Jinghang
Dolatshad, Hamid
Tittrea, Vickram
Tatwavedi, Dharamveer
Singh, Shalini
Lee, Juseong
Sun, Tianyu
Steidl, Ulrich
Shastri, Aditi
Inoue, Daichi
Abdel-Wahab, Omar
Pellagatti, Andrea
Gavathiotis, Evripidis
Boultwood, Jacqueline
Verma, Amit
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title_full ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title_fullStr ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title_full_unstemmed ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title_short ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
title_sort asxl1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455571/
https://www.ncbi.nlm.nih.gov/pubmed/34548471
http://dx.doi.org/10.1038/s41408-021-00541-0
work_keys_str_mv AT rahmaninorae asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT ramachandranandini asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT sahusrabani asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT gitegonadege asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT lopezandrea asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT pradhankith asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT bhagattushard asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT gordonmitchellshanisha asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT penabiancarivera asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT kazemimohammad asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT raokeshav asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT giriczorsi asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT maqboolshahinabano asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT olearaul asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT zhaoyongmei asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT zhangjinghang asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT dolatshadhamid asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT tittreavickram asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT tatwavedidharamveer asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT singhshalini asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT leejuseong asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT suntianyu asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT steidlulrich asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT shastriaditi asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT inouedaichi asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT abdelwahabomar asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT pellagattiandrea asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT gavathiotisevripidis asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT boultwoodjacqueline asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine
AT vermaamit asxl1mutationsareassociatedwithdistinctepigenomicalterationsthatleadtosensitivitytovenetoclaxandazacytidine